284027-34-5

Basic information

• Product Name: Isoquinoline, 1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-(trifluoromethyl)-
• CAS NO: 284027-34-5
• Molecular Formula: C12H9F6NO
• Molecular Weight: 297.1963792
• Mol File: 284027-34-5.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Isoquinoline, 1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Isoquinoline, 1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-(trifluoromethyl)-(284027-34-5)
• EPA Substance Registry System: Isoquinoline, 1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-(trifluoromethyl)-(284027-34-5)

Safety Data

• Hazardous Substances Data: 284027-34-5(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 199678-28-9 2,2,2-trifluoro-N-{2-[4-(trifluoromethyl)phenyl]ethyl}acetamide 
• 2338-75-2 4-(Trifluoromethyl)phenylacetonitrile 
• 775-00-8 2-(4-trifluoromethyl-phenyl)-ethylamine 

Downstream Products

• 1194375-56-8 7-(trifluoromethyl)isoquinoline 
• 625126-88-7 C₁₂H₈F₆INO 
• 199678-32-5 7-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Synthesis method of 7-(trifluoromethyl) isoquinoline-5-amine

The invention discloses a synthesis method of 7-(trifluoromethyl) isoquinoline-5-amine, wherein the synthesis method comprises the steps: carrying out amino protection, cyclization, hydrolysis, bromination, debromination and alkene insertion and dehydroar

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

2,6-Disubstituted piperiddines as modulators

The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.